Galegine (Guanidine Alkaloid · Metformin Botanical Prototype · Glucose-Lowering History)

Compound	Galegine (Isoamylene Guanidine)
Chemical class	Alkaloid — Guanidine Alkaloid (Isoprenoid-substituted guanidine)
CAS	543-19-5
Primary source	Galega officinalis (goat’s rue, French lilac) aerial parts
Key applications	Blood glucose lowering (historical); metformin pharmacological prototype; informational/research context
Claim strength	Moderate (historical animal data); Informational (supplement context)
Typical form	Not commercially available as a supplement — Galega herb is toxic at pharmacological doses; metformin is the pharmaceutical derivative
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Galega officinalis (goat’s rue). Galegine (isoamylene guanidine) is the guanidine alkaloid responsible for the hypoglycaemic activity of Galega officinalis and, historically, for inspiring the development of the biguanide class of antidiabetic drugs — including metformin. Historical significance: Galega officinalis (goat’s rue, French lilac) was used in medieval European medicine for diabetes and plague management. In the 1920s, galegine was isolated and found to lower blood glucose in animal models. This observation inspired the development of synthetic guanidine derivatives by Emil Werner and James Bell (synthalin, 1926) and subsequently the biguanides including metformin (synthesised 1922, clinical use 1957). Metformin remains the world’s most prescribed antidiabetic drug — used by 150+ million people globally. Galegine is therefore pharmacologically the grandfather of metformin. Supplement context: Galega officinalis at doses providing pharmacological galegine is associated with livestock toxicity — goats and sheep grazing on French lilac have died from pulmonary oedema. Galegine is not commercially available as a supplement ingredient in regulated markets due to this toxicity risk. However, its historical significance as a glucose-lowering botanical prototype is of substantial interest for the HerbIQ Compound Index educational purpose. Commercial source: Galegine is not currently in the Herbuno catalogue. Contact Herbuno for availability assessment of Galega herb extract, which requires careful toxicological characterisation.

---

Evidence for Galegine in Context

Blood glucose lowering — historical animal data: Galegine reduces blood glucose in diabetic animal models via mechanisms including AMPK activation (the same mechanism as metformin), hepatic gluconeogenesis inhibition, and peripheral glucose uptake enhancement. At pharmacological doses in animals, galegine produces similar magnitude glucose lowering to moderate metformin doses. This is the mechanistic connection to metformin. Claim strength: Moderate (animal data; human data are very limited and dated).

Galega officinalis traditional use — historical botanical context: Galega has been documented in 16th–18th century European herbals for “sweet urine” (a historical description of diabetes mellitus based on urine sweetness), fevers, and plague. Its antidiabetic traditional use across European botanical medicine from the Renaissance through the early 20th century directly preceded and inspired the guanidine research that produced metformin. This is a pharmaceutical history reference, not a clinical evidence claim.

Toxicity — Galega livestock poisoning: Galega officinalis causes severe pulmonary oedema in ruminants (sheep, goats, cattle). The toxic fraction includes galegine but also other guanidine compounds. The toxicity mechanism involves disruption of surfactant function in pulmonary alveoli. Human toxicity at pharmacological supplement doses has not been extensively studied, but the livestock toxicity history means caution is warranted at concentrations providing significant galegine exposure. This is a safety informational reference.

---

Frequently Asked Questions — Galegine

Is galegine the same as metformin?
No — galegine is the natural guanidine precursor alkaloid that inspired metformin’s development. The pharmacological connection: galegine (natural, mono-guanidine) → inspired synthalin and other synthetic guanidines → inspired biguanides (two guanidine groups linked) → metformin (N,N-dimethyl biguanide). Galegine and metformin share AMPK activation as a mechanism but are structurally completely different molecules. Metformin is more effective and better-characterised; galegine is the historical botanical prototype.

Why did galegine not become a pharmaceutical itself?
Several factors: galegine’s toxicity in animals raised safety concerns at pharmacological doses; the synthetic biguanides (including metformin) were found to be more potent, more consistent, and better-tolerated; and the pharmaceutical industry of the 1950s–1960s preferentially developed synthetic compounds over natural botanical alkaloids that could not be easily patented. The development of phenformin (biguanide, marketed 1957) and metformin (1957) made galegine commercially irrelevant even before its pharmacology was fully characterised.

Is goat’s rue safe as a herbal supplement?
Galega officinalis has a history of traditional human use (in contrast to its known ruminant toxicity) and some human clinical contexts. However, the livestock toxicity, limited human safety data, and availability of well-characterised alternatives for blood glucose management make goat’s rue a high-risk botanical for modern supplement formulation. Berberine, bitter melon, and fenugreek have stronger human evidence bases for blood glucose support with established safety profiles — they are the appropriate commercial choices rather than Galega preparations.

What is galegine’s significance for understanding natural versus pharmaceutical glucose management?
Galegine’s story illustrates a recurring pattern in pharmaceutical history: a botanical compound with empirically observed activity (Galega for diabetes, 1920s) → isolation of active principle (galegine) → synthetic optimisation (synthalins, biguanides) → clinical pharmaceutical (metformin). The natural compound is generally less potent, less consistent, and less safe than the optimised pharmaceutical, but provides the mechanistic insight that makes the pharmaceutical development possible. Understanding this progression is essential for formulators positioning botanical blood glucose support against pharmaceutical standards.

Related compounds: Colchicine, Ligustrazine, Vasicinone, Andrographolide

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery